BNOX [NASD]
Bionomics Limited
Index- P/E- EPS (ttm)-0.16 Insider Own- Shs Outstand7.28M Perf Week8.40%
Market Cap51.65M Forward P/E- EPS next Y- Insider Trans- Shs Float4.74M Perf Month-19.32%
Income- PEG- EPS next Q- Inst Own17.10% Short Float0.01% Perf Quarter-43.15%
Sales0.49M P/S104.91 EPS this Y- Inst Trans- Short Ratio0.20 Perf Half Y-
Book/sh0.94 P/B7.55 EPS next Y- ROA- Target Price0.92 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.70 - 22.00 Perf YTD-43.43%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.73% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.56% ATR0.69
Employees- Current Ratio- Sales Q/Q-72.00% Oper. Margin- RSI (14)42.88 Volatility6.80% 5.12%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close7.10
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.97K Price7.10
Recom- SMA20-7.44% SMA50-19.87% SMA200-30.79% Volume0 Change0.00%
Jan-10-22Initiated H.C. Wainwright Buy $54
Jan-10-22Initiated Evercore ISI Outperform $17
Jan-10-22Initiated Cantor Fitzgerald Overweight $52
Jan-10-22Initiated Berenberg Buy $21
Jun-27-22 06:00AM  
Jun-24-22 07:44AM  
Jun-13-22 04:30PM  
May-16-22 06:00AM  
May-10-22 08:00AM  
Feb-23-22 09:00PM  
Jan-14-22 07:06AM  
Jan-12-22 06:00AM  
Jan-05-22 05:58PM  
Jan-03-22 06:00AM  
Dec-16-21 06:00AM  
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.